2002
DOI: 10.1097/00126334-200212150-00010
|View full text |Cite
|
Sign up to set email alerts
|

Willingness to Participate and Enroll in a Phase 3 Preventive HIV-1 Vaccine Trial

Abstract: Improving community and participant knowledge about preventive HIV vaccine trials may help ensure informed consent. However, whether informing potential participants will reverse or contribute to the declining trend in WTP observed in this cohort warrants further investigation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
34
2

Year Published

2004
2004
2014
2014

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 47 publications
(38 citation statements)
references
References 20 publications
2
34
2
Order By: Relevance
“…Several studies of WTP indicated that perceived vulnerability to HIV/STD infection was associated with greater WTP in either HIV vaccine trial or HIV test (Bartholomeyczik et al, 1989;O'Connell et al, 2002). By contrast, the study among the Hong Kong cross-border sexnetworking population (Lau & Wong, 2001) and the present study did not find a significant correlation between perceived vulnerability and WTP.…”
Section: Discussioncontrasting
confidence: 96%
“…Several studies of WTP indicated that perceived vulnerability to HIV/STD infection was associated with greater WTP in either HIV vaccine trial or HIV test (Bartholomeyczik et al, 1989;O'Connell et al, 2002). By contrast, the study among the Hong Kong cross-border sexnetworking population (Lau & Wong, 2001) and the present study did not find a significant correlation between perceived vulnerability and WTP.…”
Section: Discussioncontrasting
confidence: 96%
“…This study finding is consistent with findings from other hypothetical vaccine preparedness studies (Koblin et al, 1998;Nyamathi et al, 2004;O'Connell et al, 2002;Strathdee et al, 2000). In particular, questions were raised about the stigma and discrimination due to post-vaccination seropositivity, as well as issues of confidentiality.…”
supporting
confidence: 93%
“…Finally, trial participants may not be representative of other MSM, and caution should be used in generalizing our results. Indeed, if highrisk MSM tend to enrol in vaccine trials, 1,9,10 regression to the mean could explain reductions in sexual risk behaviours that might be reported from vaccine trials lacking a comparison group that receives neither vaccine nor placebo.…”
Section: Discussionmentioning
confidence: 99%